Highlights from ASCO 2019
Highlights from ASCO 2019
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients
Comment: The success of immunotherapy means we have to change our mindset as we treat patients
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy
Ovarian cancer: Current treatments and latest advances
Latest in ovarian cancer treatment
Novel adoptive cell therapies for acute lymphoblastic leukaemia